Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of BAY 1021189 in worsening chronic heart failure with reduced ejection fraction
NL-OMON40383Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vericiguat oral suspension in heart failure with reduced ejection fraction (HFrEF) (5 arms), sponsored by Bayer. Primary endpoint: Change from baseline to week 12 in log-transformed NT-proBNP. Started May 2014; status: active, not recruiting.
02
Drugs
vericiguat oral suspension
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON40383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40383.